Malvern-based pharmaceutical company NuPathe was acquired by Israeli company Teva, which also has a regional presence, for $144 million in cash, according to a release. The publicly-traded NuPathe chose Teva’s offer over a competing offer from Chester County-based Endo Health Solutions.
The company makes a migraine painkiller called Zecuity. It was a former Science Center tenant.
NuPathe was backed by Safeguard Scientifics, making that two exits for the venture capital firm in as many months. Other investors include Quaker BioVentures, Benjamin Franklin Technology Partners, Bio Advance and Battelle Ventures. This is a classic Philadelphia technology business story: biomedical innovation developed, commercialized, invested in, gone public and then acquired by a larger pharma company.
Read our 2009 Q&A with former NuPathe CEO Jane Hollingsworth here.
Read more on the Philadelphia Inquirer.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Donate to the Journalism Fund
Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.
National AI safety group and CHIPS for America at risk with latest Trump administration firings
Immigration-focused AI chatbot wins $2,500 from Temple University to go from idea to action
How women can succeed in male-dominated trades like robotics, according to one worker who’s done it
